This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_NASAL_CAVITY_MIDDLE_EAR_EXALLC for full statistics.
Malignant neoplasm of nasal cavity and middle ear
C3_NASAL_CAVITY_MIDDLE_EAR
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
154 |
4. Check minimum number of eventsNone |
154 |
5. Include endpointsNone |
154 |
6. Filter based on genotype QC (FinnGen only) |
154 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of nasal cavity and middle ear
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of nasal cavity and sinuses
- Malignant neoplasm of nasal cavity and middle ear, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of nasal cavity and sinuses, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of respiratory system and intrathoracic organs
- Malignant neoplasm of respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 154 | 63 | 91 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 66.01 | 64.50 | 67.05 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 139
- Matched controls
- 1392
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C30.0
ICD-10 Finland
Malignant neoplasm: Nasal cavity
+∞
121.2
98
*
DHA10
NOMESCO Finland
Biopsy of cavity of nose
128.2
53.7
55
7
8070/3-C30.0
ICD-O-3
Squamous cell carcinoma, NOS, of nasal cavity
+∞
45.3
41
*
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
116.8
45.3
47
6
UDH02
NOMESCO Finland
Rhinopharyngoscopy
22.3
42.7
66
54
DHB10
NOMESCO Finland
Excision of lesion of internal nose
103.4
36.0
38
5
WF003
NOMESCO Finland
Adjuvant radiotherapy
25.9
29.2
41
22
DM1DG
NOMESCO Finland
Paranasal sinuses and face area very extensive MRI examination with high intensity magnet
+∞
23.6
22
*
8720/3-C30.0
ICD-O-3
Malignant melanoma, NOS, of nasal cavity
+∞
23.6
22
*
130
Kela drug reimbursment
Malignant tumour
12.4
23.2
44
50
UDM02
NOMESCO Finland
Sinoscopy
34.6
22.0
28
10
DNB30
NOMESCO Finland
Excision of lesion of ethmoidal sinus
+∞
20.3
19
*
R04.0
ICD-10 Finland
Epistaxis
8.8
18.0
41
63
WF002
NOMESCO Finland
Radical radiotherapy
10.5
17.4
35
43
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
32.3
17.1
22
8
DJB10
NOMESCO Finland
Excision of septum of nose
+∞
17.0
16
*
D38.58
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of other respiratory organ
+∞
17.0
16
*
XX3DW
NOMESCO Finland
Time consuming IT work
7.5
16.9
43
78
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
4.8
16.7
78
292
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
14.3
16.5
28
24
A03FA01
ATC
metoclopramide; systemic, rectal
5.2
15.5
57
163
H02AB02
ATC
dexamethasone; systemic
7.5
14.9
37
64
DPA30
NOMESCO Finland
Sphenotomy
+∞
14.8
14
*
A04AA01
ATC
ondansetron; systemic, rectal
11.0
14.6
28
31
DM1BD
NOMESCO Finland
Extensive CT of paranasal sinuses and face area
48.0
14.5
17
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
34.1
14.3
18
6
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
15.0
14.0
23
18
C72.2
ICD-10 Finland
Malignant neoplasm: Olfactory nerve
+∞
13.8
13
*
9522/3-C30.0
ICD-O-3
Olfactory neuroblastoma of nasal cavity
+∞
13.8
13
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
15.1
13.5
22
17
EP1AE
NOMESCO Finland
Neck ultrasound examination
10.8
13.5
26
29
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
25.6
13.3
18
8
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
55.6
13.1
15
*
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
12.7
12
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
16.7
12.2
19
13
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
9.3
12.0
25
32
UDQ12
NOMESCO Finland
Flexible laryngoscopy
9.0
11.8
25
33
9680/3-C30.0
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of nasal cavity
+∞
11.6
11
*
DPC35
NOMESCO Finland
Extensive endoscopic excision of lesion or neoplasm extending to more than one paranasal sinus
+∞
11.6
11
*
DM1CG
NOMESCO Finland
Paranasal sinuses and face area extensive MRI examination with high intensity magnet
+∞
11.6
11
*
DHB40
NOMESCO Finland
Conchotomy
130.4
11.6
12
*
SAA03
NOMESCO Finland
Extended examination of mouth
3.7
11.6
70
301
A04AA02
ATC
granisetron; systemic, transdermal
7.7
11.5
27
42
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
8.6
11.1
24
33
ZXC95
NOMESCO Finland
Use of surgical navigator
118.6
10.6
11
*
AAE99
NOMESCO Finland
Other operation by cranial base approach
+∞
10.5
10
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
20.8
10.5
15
8
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
8.8
10.4
22
29
N02AA05
ATC
oxycodone; systemic
4.3
10.4
42
126
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
3.3
10.3
73
345
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
7.2
10.3
25
41
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
43.5
10.1
12
*
L03AA02
ATC
filgrastim; parenteral
18.5
10.1
15
9
A07AA02
ATC
nystatin; oral
7.7
9.9
23
35
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
5.6
9.8
29
62
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
32.6
9.6
12
*
DMA00
NOMESCO Finland
Biopsy of maxillary antrum
107.0
9.5
10
*
EEB00
NOMESCO Finland
Partial excision of maxilla
+∞
9.5
9
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
10.2
9.4
18
20
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
53.4
8.8
10
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
21.7
8.6
12
6
C31.0
ICD-10 Finland
Malignant neoplasm: Maxillary sinus
+∞
8.4
8
*
D38.51
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of other accessory sinus
+∞
8.4
8
*
C31.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of accessory sinuses
+∞
8.4
8
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
9.1
8.4
17
21
WX402
NOMESCO Finland
General anaesthesia
3.9
8.3
36
113
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.5
8.2
21
37
WF049
NOMESCO Finland
Radiotherapy of metastasis
10.4
8.0
15
16
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
16.3
7.9
12
8
J34.8
ICD-10 Finland
Other specified disorders of nose and nasal sinuses
26.7
7.7
10
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.9
7.5
55
254
DMB30
NOMESCO Finland
Transmaxillary excision of lesion of maxillary antrum
84.4
7.5
8
*
DLW99
NOMESCO Finland
Other plastic operations on nose
84.4
7.5
8
*
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
16.9
7.4
11
7
C03.0
ICD-10 Finland
Malignant neoplasm: Upper gum
+∞
7.4
7
*
L01CB01
ATC
etoposide; systemic
+∞
7.4
7
*
DHB01
NOMESCO Finland
Partial excision of external nose
+∞
7.4
7
*
Z51.5
ICD-10 Finland
Palliative care
5.2
7.3
22
48
SAA04
NOMESCO Finland
Special inverstigation of mouth
9.6
7.2
14
16
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
21.4
7.2
10
5
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
31.8
7.2
9
*
AA1BD
NOMESCO Finland
Extensive CT of head and brain
9.0
7.0
14
17
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
4.2
6.6
25
69
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.6
6.6
75
436
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
15.3
6.5
10
7
R4190
NOMESCO Finland
Nutritional therapy
8.8
6.5
13
16
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
11.8
6.4
11
10
DMB00
NOMESCO Finland
Endonasal trephine of maxillary antrum
28.1
6.3
8
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
28.1
6.3
8
*
8200/3-C30.0
ICD-O-3
Adenoid cystic carcinoma of nasal cavity
+∞
6.3
6
*
DKW99
NOMESCO Finland
Other procedures for control of epistaxis
+∞
6.3
6
*
D36.7
ICD-10 Finland
Benign neoplasm: Other specified sites
+∞
6.3
6
*
8020/3-C30.0
ICD-O-3
Carcinoma, undifferentiated, NOS, of nasal cavity
+∞
6.3
6
*
QAE40
NOMESCO Finland
Repair of anomaly or lesion after disease of skin of head or neck
+∞
6.3
6
*
AAE05
NOMESCO Finland
Nasoendoscopic closure of cerebrospinal fluid fistula
+∞
6.3
6
*
R22.0
ICD-10 Finland
Localized swelling, mass and lump, head
8.3
6.3
13
17
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
5.7
6.3
17
33
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
8
26.83
14.18
1.2
1.1
—
—
—
0
0
104
628
3.02
9.54
7.0
6.5
1.2
1.2
mmol/l
0.49
86
535
94
568
2.68
8.10
6.7
4.1
—
—
—
0
0
107
709
2.67
7.34
15.4
9.9
3.9
4.1
e9/l
0.43
96
623
8
7
11.96
4.84
1.9
2.1
—
—
—
0
0
9
11
8.60
4.63
1.2
1.4
—
—
—
0
0
30
139
2.44
4.17
2.0
1.7
—
—
—
0
0
32
154
2.36
4.10
5.9
6.3
0.8
1.0
mmol/l
0.08
23
122
12
34
3.74
3.85
1.2
1.4
—
—
—
0
0
29
138
2.36
3.80
2.0
1.7
—
—
—
0
0
21
89
2.57
3.50
1.3
1.4
—
—
—
0
0
13
42
3.29
3.46
1.9
2.3
—
—
—
0
0
8
16
5.21
3.09
2.1
1.7
13.3
18.6
ug/l
—
8
16
6
8
7.74
3.08
1.8
2.1
—
—
—
0
0
48
299
1.88
3.08
2.2
2.4
—
—
—
0
0
9
21
4.48
3.04
1.1
1.3
—
—
—
0
0
5
6
8.56
2.77
2.4
1.0
—
—
—
0
0
98
1159
0.58
2.64
3.8
4.9
1.4
1.4
mmol/l
0.43
90
1056
7
15
4.83
2.63
1.9
1.1
—
—
—
0
0
33
195
1.88
2.45
2.2
1.8
—
—
—
0
0
19
92
2.22
2.39
4.4
2.7
64.6
59.9
ml/min/173m2
—
8
36
53
364
1.70
2.38
2.6
3.1
0.2
0.5
e6/l
1.60
37
274
24
132
1.97
2.19
5.7
3.6
—
—
—
0
0
64
470
1.62
2.19
2.8
3.2
—
—
—
0
0
9
30
3.12
2.18
1.4
1.4
—
—
—
0
0
97
1129
0.62
2.08
3.6
4.3
1.4
1.3
mmol/l
0.57
87
1024
18
92
2.08
2.00
2.9
2.6
113.0
168.9
ng/l
0.72
18
81
7
21
3.44
1.99
1.1
1.4
—
—
—
0
0
102
1164
0.63
1.84
3.9
4.9
4.6
4.5
mmol/l
0.31
95
1068
12
232
0.48
1.70
1.2
1.2
9.4
1.8
u/ml
—
5
59
115
1011
1.54
1.53
22.8
16.2
37.1
39.9
%
2.11
83
678
9
37
2.52
1.50
1.9
1.6
—
—
—
0
0
107
1193
0.66
1.49
4.1
5.4
2.7
2.7
mmol/l
0.06
97
1082
5
19
2.68
1.22
1.0
1.2
—
—
—
0
0
45
342
1.45
1.22
4.4
3.0
323.2
8415.0
umol/l
1.98
40
282
8
40
2.05
1.14
6.5
4.7
70.9
29.4
mg/l
—
8
33
128
1179
1.51
1.09
26.3
15.4
25.5
23.8
mg/l
0.30
115
969
19
122
1.64
1.09
2.5
4.0
3.0
2.0
mmol/l
0.89
19
83
5
22
2.31
1.04
2.8
1.1
—
—
—
0
0
5
22
2.31
1.04
2.8
1.1
—
—
—
0
0
93
815
1.36
1.04
4.1
4.4
391.9
521.1
e6/l
—
7
17
5
23
2.21
0.99
1.8
2.0
—
—
—
0
0
11
62
1.83
0.97
1.9
1.6
—
—
—
0
0
19
126
1.58
0.97
2.5
3.9
6.1
5.7
kpa
1.15
19
118
42
521
0.73
0.92
2.0
2.0
86.6
92.0
pmol/l
0.40
23
260
6
29
2.11
0.90
1.7
1.1
—
—
—
0
0
116
1066
1.36
0.86
4.8
4.6
2.2
2.0
mu/l
0.56
110
949
6
32
1.91
0.82
1.2
1.8
—
—
—
0
0
7
40
1.78
0.72
7.3
4.7
24.1
238.8
mg/l
—
7
33
10
61
1.68
0.70
3.0
4.5
26.9
24.1
mmol/l
—
10
51
120
1126
1.30
0.63
24.0
14.7
82.7
77.7
ml/min/173m2
2.18
104
919
5
30
1.69
0.62
1.2
1.8
—
—
—
0
0
110
1170
0.79
0.60
4.5
5.0
6.1
6.1
mmol/l
0.05
100
1061
0
21
0.00
0.60
0.0
4.1
—
34.9
—
0
7
9
61
1.50
0.55
5.9
2.0
—
—
—
0
0
9
65
1.41
0.51
1.4
1.6
—
—
—
0
0
40
341
1.23
0.49
3.0
3.9
0.0
0.0
estimate
0.00
14
111
132
1266
1.30
0.49
30.0
18.3
75.0
81.9
umol/l
3.15
132
1266
5
31
1.63
0.43
1.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
4.0
—
83.2
—
0
17
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
108
1134
0.84
0.40
5.2
6.5
40.7
40.8
mmol/mol
0.03
99
1047
10
72
1.42
0.38
1.7
1.8
—
—
—
0
0
7
52
1.36
0.31
7.1
2.1
40.7
38.1
g/l
—
7
45
7
53
1.34
0.31
7.7
2.1
0.5
0.5
g/l
—
7
48
18
214
0.82
0.28
1.9
2.3
18.5
13.0
umol/l
0.44
18
186
5
75
0.66
0.26
1.6
1.9
—
—
—
0
0
64
598
1.12
0.25
3.0
3.8
0.0
0.0
estimate
0.00
15
116
134
1308
1.19
0.25
34.0
22.7
126.1
135.6
g/l
8.86
134
1288
13
106
1.25
0.24
4.9
2.5
63.9
66.5
g/l
0.67
13
96
5
38
1.33
0.23
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
19.2
—
0
5
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
52
556
0.90
0.20
3.6
3.9
1207.9
47.2
ng/l
0.49
38
401
31
283
1.12
0.17
1.6
1.8
2.8
1.3
mg/l
1.00
26
224
51
481
1.09
0.16
3.2
4.0
—
—
—
0
0
61
639
0.92
0.15
2.7
2.6
—
—
—
0
0
22
202
1.10
0.11
2.8
2.8
0.0
1.7
e6/l
—
10
117
18
197
0.90
0.10
1.7
2.3
2.3
2.3
g/l
0.11
18
172
14
126
1.12
0.09
1.4
1.3
—
—
—
0
0
7
68
1.03
0.08
1.7
2.7
0.7
1.3
%
—
7
68
63
612
1.05
0.07
3.2
3.9
0.0
0.0
estimate
0.00
14
108
8
78
1.03
0.07
2.3
1.3
—
—
—
0
0
44
455
0.95
0.06
4.7
4.4
23.3
22.0
%
0.18
26
231
18
168
1.08
0.06
12.3
7.0
—
—
—
0
0
62
605
1.04
0.05
4.2
5.2
0.0
0.0
estimate
0.00
15
119
25
261
0.95
0.04
1.4
1.6
1098.0
1208.4
nmol/l
0.30
20
186
47
478
0.98
0.01
2.0
2.4
69.9
76.1
nmol/l
0.97
42
412
15
157
0.95
0.01
1.1
1.4
—
—
—
0
0
11
109
1.01
0.00
2.3
2.9
4.8
4.3
kpa
0.24
11
100
22
216
1.02
0.00
2.7
2.6
0.4
0.9
e6/l
—
10
130
0
6
0.00
0.00
0.0
2.2
—
17.6
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
1068.0
—
0
7
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
72.0
—
0
5
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
9.8
—
0
7
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_NASAL_CAVITY_MIDDLE_EAR – Malignant neoplasm of nasal cavity and middle ear
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).